Liminatus Pharma, Inc. LIMN
Set alert
2.82 USD -0.08 -2.76%
At close · Oct 30
2.83 +0.01 +0.35%
After hours · Oct 30, 4:00 PM ET
2.75 Day range 3.00
2.82 52-week range 102.50
- YTD
- -90.75%
- 1 year
- -96.00%
- Open
- 2.98
- Prev close
- 2.90
- Mkt cap
- 3.79M
- Vol
- 12.97K
- Avg vol
- 223.18K
- EPS
- -23.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.75
- High
- 3.00
3M chart
Events in this range
- Aug 21, 2026Split: 1 for 50
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
Financials — quick view
LIMN Revenue — quarterly 0
LIMN Net income — quarterly -1.41M
LIMN EPS — quarterly -1.50
News
- Liminatus Pharma Regains Compliance With Nasdaq’s Minimum Bid Price Rule
- Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
- Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Liminatus Pharma Board Adopts Resolutions Approving Reverse Stock Split Of Its Common Stock At Ratio Of 1-For-50
- Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on LIMN — it syncs with the Stock Master app.